Introduction:

hemophilia is an inherited disease that prevents proper blood clotting and constitutes 80 to 85% of all hereditary bleeding diathesis. It is caused by decreased activity of factor VIII (hemophilia A) or factor IX (hemophilia B).

Case report:

18-year-old adolescent with white skin, attended at the Hematology Department of the Pepe Portilla Pediatric Teaching Hospital in Pinar del Río, who in the neonatal stage presented a hematoma on the right thigh after the administration of the hepatitis B vaccine associated to bleeding from the puncture sites. At 3 months of age he presented his first hemarthrosis in the right knee, an unusual event at this stage of life due to poor mobility. At 11 years of age, physiotherapy treatment was started with hydrotherapy with encouraging results in the recovery of muscle tone. At the beginning of 2015, when she was 12 years old, she began to use the prophylaxis regimen with F VIII three times a week, which together with the rehabilitation sessions, made possible the decrease of bleeding, as well as deambulation, incorporating in person and without the support of wheelchairs to the teaching scenario.

Conclusions:

it is concluded that the use of emicizumab in a patient with hemophilia A without inhibitors, presented a high safety profile, as well as a high efficiency in the prevention of bleeding tendency.

        · resumen en Español     · texto en Español     · Español ( pdf )